MARKSANS — Marksans Pharma Share News
0.000.00%
Last trade - 00:00- IN₹130.01bn
- IN₹123.80bn
- IN₹29.51bn
Brief: Marksans Pharma Ltd To Acquire 100% Of Netherlands-Based Qliniq B.V
India's Marksans Pharma jumps to 10-month high after Q4 profit rise
Brief: Marksans Pharma March-Quarter Consol Net Profit 1.48 Billion Rupees
Brief: Marksans Pharma Ltd Receives USFDA Approval For Benzonatate Capsules USP, 100 Mg & 200 Mg
Brief: Marksans Pharma Dec-Quarter Consol Net Profit 1.13 Billion Rupees
Brief: Marksans Pharma Says UK Subsidiary Receives Marketing Authorization For Cetirizine
India's Marksans Pharma rises after unit gets marketing approval for drug
Brief: Marksans Pharma Unit Receives USFDA Approval For Loperamide Tablets
Brief: Marksans Pharma Says Relonchem Receives UK MHRA Approval For Mefenamic Acid Tablets
Brief: Marksans Pharma Sept-Quarter Consol Net Profit 982.5 Million Rupees
Brief: Marksans Pharma Says Us FDA Conducted CGMP Inspection At Marksans Pharma's Goa Facility
Brief: Marksans Pharma Says Relonchem Receives UK Authorization For Exemestane Tablets
India's Marksans Pharma rises after UK unit gets marketing authorisation
India's Marksans Pharma slumps 10% as quarterly profit drops
Brief: Marksans Pharma Re-Appointed Mark Saldanha As MD
Brief: Marksans Pharma Re-Appoints Mark Saldanha As Managing Director
India's Marksans Pharma gains as US FDA completes inspection at unit
Brief: Marksans Pharma Says Subsidiary Receives EIR From USFDA
Brief: Marksans Pharma Receives Marketing Authorization For Oxybutynin Hydrochloride Oral Solution